Reliability, Satisfaction and Effectiveness of Benralizumab Home Self-Administration in Patients with Severe Eosinophilic Asthma in Real-World Practice: The Auto-Benra Study

References

• Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344–1353.e2. doi:10.1016/j.jaci.2010.04.004
   PubMed Web of Science ®Google Scholar
• Bleecker ER, FitzGerald JM, Chanez P, et al. Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet. 2016;388:2115–2127. doi:10.1016/S0140-6736(16)31324-1
   PubMed Web of Science ®Google Scholar
• FitzGerald JM, Bleecker ER, Nair P, et al. Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2016;388:2128–2214. doi:10.1016/S0140-6736(16)31322-8
   PubMed Web of Science ®Google Scholar
• Nair P, Wenzel S, Rabe KF, et al. Oral glucocorticoid-sparing effect of benralizumab in severe asthma. N Engl J Med. 2017;376(25):2448–2458. doi:10.1056/NEJMoa1703501
   PubMed Web of Science ®Google Scholar
• Chipps BE, Newbold P, Hirsch I, Trudo F, Goldman M. Benralizumab efficacy by atopy status and serum immunoglobulin E for patients with severe, uncontrolled asthma. Ann Allergy Asthma Immunol. 2018;120(5):504–511.e4. doi:10.1016/j.anai.2018.01.030
   PubMed Web of Science ®Google Scholar
• Liu T, Wang F, Wang G, Mao H. Efficacy and safety of benralizumab in patients with eosinophilic asthma: a meta-analysis of randomized placebo-controlled trials. Front Med. 2018;12(3):340–349. doi:10.1007/s11684-017-0565-0
   PubMed Web of Science ®Google Scholar
• Tetteh EK, Morris S, Titcheneker-Hooker N. Discrete-choice modelling of patient preferences for modes of drug administration. Health Econ Rev. 2017;7(1):26. doi:10.1186/s13561-017-0162-6
   PubMed Web of Science ®Google Scholar
• Stoner KL, Harder H, Fallowfield LJ, Jenkins VA. Intravenous versus subcutaneous drug administration. Which do patients prefer? A systematic review. Patient. 2014. doi:10.1007/s40271-014-0075-y
   PubMedGoogle Scholar
• Scalone L, Sarzi-Puttini P, Sinigaglia L, et al. Patients’, physicians’, nurses’, and pharmacists’ preferences on the characteristics of biologic agents used in the treatment of rheumatic diseases. Patient Prefer Adherence. 2018;12:2153–2168. doi:10.2147/PPA.S168458
   PubMed Web of Science ®Google Scholar
• Huynh TK, Ostergaard A, Egsmose C, Madsen OR. Preferences of patients and health professionals for route and frequency of administration of biologic agents in the treatment of rheumatoid arthritis. Patient Prefer Adherence. 2014;8:93–99. doi:10.2147/PPA.S55156
   PubMed Web of Science ®Google Scholar
• Pozzilli C, Schweikert B, Ecari U, Oentrich W. Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis — results of the BetaPlus observational cohort study. J Neurol Sci. 2011;307(1–2):120–126. doi:10.1016/j.jns.2011.04.026
   PubMed Web of Science ®Google Scholar
• Ferguson GT, Mansur AH, Jacobs JS, et al. Assessment of an accessorized pre-filled syringe for home-administered benralizumab in severe asthma. J Asthma Allergy. 2018;11:63–72. doi:10.2147/JAA.S157762
   PubMed Web of Science ®Google Scholar
• Martin UJ, Fuhr R, Forte P, et al. Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results [published online ahead of print, 2019 Sep 20]. J Asthma. 2019;2019:1–9.
   Google Scholar
• Ferguson GT, Cole J, Aurivillius M, et al. Single-use autoinjector functionality and reliability for at-home administration of benralizumab for patients with severe asthma: GRECO trial results. J Asthma Allergy. 2019;12:363–373. doi:10.2147/JAA.S224266
   PubMed Web of Science ®Google Scholar
• Benralizumab Spanish official prescribing information. Available from: https://cima.aemps.es/cima/pdfs/es/ft/1171252001/FT_1171252001.pdf. Accessed May 2, 2022.
   Google Scholar
• The British Thoracic Society. COVID-19: information for the respiratory community; 2022. Available from: https://www.brit-thoracic.org.uk/about-us/covid-19-information-for-the-respiratory-community/. Accessed May 2, 2022.
   Google Scholar
• Societa' Italiana di Allergologia, Asma ed Immunologia Clinica. Documento di Indirizzo SIAAIC per Pazienti Allergici Respiratori ed i Centri di Allergologia, Asma e Immunologia Clinica [SIAAIC recommendations for respiratory allergy patients and centers for allergy, asthma and immunology clinic]; 2020. Available from: http://www.siaaic.org/wp-content/uploads/2020/04/Documento-di-Indirizzo-SIAAIC.pdf. Accessed May 2, 2022. Italian.
   Google Scholar
• Busse WW. Biological treatments for severe asthma: a major advance in asthma care. Allergol Int. 2019;68(2):158–166. doi:10.1016/j.alit.2019.01.004
   PubMedGoogle Scholar
• Poddighe D, Kovzel E. Impact of anti-type 2 inflammation biologic therapy on COVID-19 clinical course and outcome. J Inflamm Res. 2021;14:6845–6853. doi:10.2147/JIR.S345665
   PubMed Web of Science ®Google Scholar
• Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices. 2016;9:361–369. doi:10.2147/MDER.S113752
   Google Scholar
• Stauffer VL, Sides R, Lanteri-Minet M, et al. Comparison between prefilled syringe and autoinjector devices on patient-reported experiences and pharmacokinetics in galcanezumab studies. Patient Prefer Adherence. 2018;12:1785–1795. doi:10.2147/PPA.S170636
   PubMed Web of Science ®Google Scholar
• Guía Española para el Manejo del Asma [Spanish guidelines for the management of asthma]. GEMA5.0 [homepage]; 2022. Available from: www.gemasma.com. Accessed May 2, 2022. Spanish.
   Google Scholar
• Vega JM, Badia X, Badiola C, et al. Validation of the Spanish version of the Asthma Control Test (ACT). J Asthma. 2007;44(10):867–872. doi:10.1080/02770900701752615
   PubMed Web of Science ®Google Scholar
• Sanjuàs C, Alonso J, Sanchís J, et al. Cuestinario de calidad de vida en pacientes con asma: la versión española del Asthma Quality of Life Questionnaire [The quality-of-life questionnaire with asthma patients: the Spanish version of the Asthma Quality of Life Questionnaire]. Arch Bronconeumol. 1995;31(5):219–226. Spanish. doi:10.1016/S0300-2896(15)30927-3
   PubMedGoogle Scholar
• Crimi C, Campisi R, Noto A, et al. Comparability of asthma control test scores between self and physician-administered test. Respir Med. 2020;170:106015. doi:10.1016/j.rmed.2020.106015
   PubMed Web of Science ®Google Scholar
• Kavanagh JE, Hearn AP, Dhariwal J, et al. Real-world effectiveness of benralizumab in severe eosinophilic asthma. Chest. 2021;159(2):496–506. doi:10.1016/j.chest.2020.08.2083
   PubMed Web of Science ®Google Scholar
• Bagnasco D, Brussino L, Bonavia M, et al. Efficacy of Benralizumab in severe asthma in real life and focus on nasal polyposis. Respir Med. 2020;171:106080. doi:10.1016/j.rmed.2020.106080
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, García-Ruiz AJ, Levy Abitbol RC, et al. Real-life cost-effectiveness of benralizumab in patients with severe asthma. Respir Res. 2021;22(1):163. doi:10.1186/s12931-021-01758-0
   PubMed Web of Science ®Google Scholar
• Padilla-Galo A, Levy-Abitbol R, Olveira C, et al. Real-life experience with benralizumab during 6 months. BMC Pulm Med. 2020;20(1):184. doi:10.1186/s12890-020-01220-9
   PubMed Web of Science ®Google Scholar
• Miralles López JC, Escudero Pastor AI, Carbonell Martínez A, Navarro Garrido C, Pacheco B, Petryk Petryk Y. Quality of life in severe asthmatic patients treated with benralizumab. Eur Ann Allergy Clin Immunol. 2021. doi:10.23822/EurAnnACI.1764-1489.218
   PubMed Web of Science ®Google Scholar
• Yamada H, Nakajima M, Matsuyama M, et al. Identification of distinct phenotypes related to benralizumab responsiveness in patients with severe eosinophilic asthma. PLoS One. 2021;16(3):e0248305. doi:10.1371/journal.pone.0248305
   PubMed Web of Science ®Google Scholar
• Pelaia C, Crimi C, Benfante A, et al. Therapeutic effects of benralizumab assessed in patients with severe eosinophilic asthma: real-life evaluation correlated with allergic and non-allergic phenotype expression. J Asthma Allerg. 2021;Volume 14:163–173. doi:10.2147/JAA.S297273
   Web of Science ®Google Scholar
• Watanabe S, Suzukawa M, Tashimo H, et al. High serum cytokine levels may predict the responsiveness of patients with severe asthma to benralizumab. J Asthma. 2021;1–9. doi:10.1080/02770903.2021.1942039
   PubMed Web of Science ®Google Scholar
• Watanabe H, Shirai T, Hirai K, et al. Blood eosinophil count and FeNO to predict benralizumab effectiveness in real-life severe asthma patients. J Asthma. 2021;1–9. doi:10.1080/02770903.2021.1963769
   PubMed Web of Science ®Google Scholar
• Di Bona D, Crimi C, D’Uggento AM, et al. Effectiveness of benralizumab in severe eosinophilic asthma: distinct sub-phenotypes of response identified by cluster analysis. Clin Exp Allergy. 2021;52:312–323. doi:10.1111/cea.14026
   PubMed Web of Science ®Google Scholar
• Nolasco S, Crimi C, Pelaia C, et al. Benralizumab effectiveness in severe eosinophilic asthma with and without chronic rhinosinusitis with nasal polyps: a real-world multicenter study. J Allergy Clin Immunol Pract. 2021;9(12):4371–4380.e4. doi:10.1016/j.jaip.2021.08.004
   PubMed Web of Science ®Google Scholar
• Menzella F, Fontana M, Galeone C, et al. Real world effectiveness of benralizumab on respiratory function and asthma control. Multidiscip Respir Med. 2021;16(1):785. doi:10.4081/mrm.2021.785
   PubMed Web of Science ®Google Scholar
• Menzella F, Ruggiero P, Galeone C, Scelfo C, Bagnasco D, Facciolongo N. Significant improvement in lung function and asthma control after benralizumab treatment for severe refractory eosinophilic asthma. Pulm Pharmacol Ther. 2020;64:101966. doi:10.1016/j.pupt.2020.101966
   PubMed Web of Science ®Google Scholar
• Holguin F, Cardet JC, Chung KF, et al. Management of severe asthma: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J. 2020;55(1):1900588. doi:10.1183/13993003.00588-2019
   PubMed Web of Science ®Google Scholar
• Shirai T, Akamatsu T, Hirai K, et al. Oscillometry improves earlier than spirometry after benralizumab initiation in severe asthma. Allergy. 2020;75(10):2678–2680. doi:10.1111/all.14339
   PubMed Web of Science ®Google Scholar
• Canonica GW, Harrison TW, Chanez P, et al. Benralizumab improves symptoms of patients with severe, eosinophilic asthma with a diagnosis of nasal polyposis. Allergy. 2021;77:150–161.
   PubMed Web of Science ®Google Scholar